Latest news

February 11, 2020

BXTAccelyon and Hitachi Medical Systems to support #TRexit

As the national campaign to eradicate traditional transrectal (TRUS) biopsies from the prostate cancer pathway gains momentum, BXTAccelyon is pleased to announce a training and promotion partnership with Hitachi Medical Systems UK.

Approaching 100 centres across England are now using the PrecisionPoint biopsy device, which allows transperineal (TP) biopsies to be conduct...

February 20, 2019

Dear Secretary of State,

Last year Mrs May pledged £75 million funding for prostate cancer research, paving the way for breakthroughs in the diagnosis, treatment and prevention of this most prevalent cancer in men in the UK. The recent NICE Guidance on prostate cancer has made a positive recommendation that all patients referred with suspected prostate cancer should have an MRI scan before a decision is made on prostate biopsy....

January 15, 2019

Chris Stone was a 66-year-old physically active, semi-retired senior banking executive when he was diagnosed with prostate cancer in early February 2017.

It was picked up during an annual private health check that indicated his PSA (prostate specific antigen) level had jumped from 3.5 to 5.4 in one year.

“I didn’t have any symptoms and felt fine. In fact, I go to the gym three times a week and play golf to a reasonable standard...

December 19, 2018

Back on the 30th November, in collaboration with Rick Popert and his team, we hosted our first ‘Urologists against TRUS biopsy’, or #TREXIT meeting at Guy's and St Thomas' NHS Foundation Trust. Hosted by Rick Popert and with over 35 of the NHS’ leading urologists and prostate cancer authorities including Prostate Cancer UK and the Accountable Cancer Network in attendance, the objective for the day was to discuss how TRUS biops...

September 27, 2018

The Galway Clinic is a state of the art private hospital in Galway, Ireland that provides 24-hour healthcare services. The clinic introduced Oncology treatment and Cardiac services to the West of Ireland in 2004 and provides the widest range of treatment for prostate cancer in Ireland. As a pioneering institution in prostate cancer treatment, it is of the utmost importance for the clinic to ensure it stays at the forefront of...

September 25, 2018

The Edinburgh Cancer Centre - Western General Hospital Edinburgh is an internationally recognised cutting-edge centre of excellence in innovative biomedical research and is one of only two hospitals in Scotland to offer specialist low-dose rate brachytherapy (LDR-B) treatment for prostate cancer. The first Scottish Centre to offer prostate brachytherapy in 2001, Edinburgh currently treats approximately 80 patients with LDR-B...

September 5, 2018

The 63-year-old cab driver from Musselburgh was taking an old friend on a short hire three years ago when their brief conversation turned to getting tested for prostate cancer.

Coincidentally, Andy was due at his GP’s surgery that day for a routine cholesterol blood test.

On his friend’s recommendation, he asked for a PSA (prostate specific antigen) blood test, a first step to diagnosing the disease available to men over 50.


August 15, 2018

Prostate cancer (PCa) was the second largest cause of cancer death among males in 20151, much of which is attributable to patients with intermediate-and-high-risk PCa where 10-year survival is as low as 25% without treatment2. Yet despite the prevalence, burden and human impact of the disease, one of the most effective treatment options for PCa is commonly overlooked: brachytherapy. A series of misconceptions continues to thwa...

The recent news of Theresa May’s announcement of £75m plans to drive prostate cancer research is a huge step forward in the diagnosis of Prostate Cancer. At present, patients are in danger of being diagnosed at too late a stage and subsequently are then not being fully educated on the variety of treatments available to them.

New guidelines around PSA testing promise to transform prostate cancer outcomes in Australia. The guidelines, which recommend that asymptomatic men between the ages of 50-69 are offered PSA testing every two years1, replace US Preventative Services Task Force guidelines and previous differing guidelines in Australia that some urologists blame for an increase in presentations with metastatic prostate cancer2. Certainly, when sc...

Please reload

Recent Posts

December 19, 2018